Abstract
Ovarian clear cell cancers (OCCC) represent 5–25% of ovarian cancers. Histologic diagnosis remains a significant challenge, often misclassifying the cancers. These tumours tend to present at earlier stages, and their aetiology is linked to endometriosis and genetic aberrations such as ARID1A and PIK3CA mutations. When compared, stage for the stage with other epithelial ovarian cancers, patients with early-stage OCCC have a better prognosis than patients with high-grade serous tumours. Patients with Stage IC–IV have a relatively poor prognosis, and efforts should centre on discovering more effective treatment strategies. Ovarian CCC is a biologically distinct entity, different from high-grade serous epithelial ovarian cancers (EOC). Future research is needed to explore targeted therapy’s role in managing ovarian CCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
